一种新的^3H—TdR掺入法抗癌药敏试验

作者对琼脂-液体双层抗癌药敏试验系统加以改进,建立了更为简便有效的试验系统。经对84例临床肺癌患者活标本测试,成功率达85%。将肺癌细胞对长春新碱(VCR),丝裂霉素(MMC),顺铂(DDP)和阿霉素(ADM)的敏感界限,以1/10血液峰值浓度下细胞存活率表示,并分别定为50%、40%、30%和30%时,测试结果与文献报告的肺癌临床单药化疗有效率近似。本法与干细胞法作平行试验测试10个肺癌细胞系对4种药物的敏感性,两法符合率为83%。测试4例肺癌活检标本,两法符合第为100%。作者认为本试验系统具有临床推广应用价值。

An in Vitro Drug Sensitivity Test Using a Higher ~3H-TdR Incorporation and a Modified Human Tumor Stem Cell Assay

An in vitro drug sensitivity test was developed to evaluate the lethal effects of drugs on human pulmonary carcinoma cells (HPCC). This method was a variant and combination of Human Tumor Stem Cell Assay (HTSCA) and a short-term test using ~3H-TdR incorporation. It comsisted of a cell containing liquid top layer and a soft agar bottom layer in 24-well microplates. The medium was RPMI 1640 supplemented with 20% malignant pleual effusion, which could enhance ~3H-TdR incorporation into malignant cells much more than FBS. 85% HPCC yielded good reaults. When 50%,40%,30% and30% of cell sruvival rate defined as sensitivity-threshold for VCR, MMC, DDP and ADM respectively, in the vitro effectiveness were close to those of clinical single-drug treatment in HPCC by Wright et al. This method was also compared with HTSCA in ten human lung cancer cell lines and four pulmonary carcinoma tissues. The agreement rotes were 83% and 100% respectively. Thus we presume this system is more useful for oncological clinics than the others.